Cargando…

The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies

OBJECTIVE: We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients. MATERIALS AND METHODS: We searched PubMed, EMBASE, and the Cochrane Library for relevant article...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Meng, Jin, Ying, Ma, Li, Zhang, Yan-Yan, Pan, Ling-Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823572/
https://www.ncbi.nlm.nih.gov/pubmed/29492221
http://dx.doi.org/10.18632/oncotarget.23808
_version_ 1783301900632850432
author Qin, Meng
Jin, Ying
Ma, Li
Zhang, Yan-Yan
Pan, Ling-Ya
author_facet Qin, Meng
Jin, Ying
Ma, Li
Zhang, Yan-Yan
Pan, Ling-Ya
author_sort Qin, Meng
collection PubMed
description OBJECTIVE: We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients. MATERIALS AND METHODS: We searched PubMed, EMBASE, and the Cochrane Library for relevant articles. All statistical analyses were performed in Review Manager 5.3.5. RESULTS: In two randomized controlled trials (RCTs), there was no significant difference in overall survival (OS) (HR = 0.93, 95% CI: 0.81–1.06) or progression-free survival (PFS) (HR = 0.97, 95% CI: 0.86–1.09). Few adverse events (HR = 0.37, 95% CI: 0.19–0.72) and a high optimal debulking surgery rate (HR = 1.69, 95% CI: 1.50–1.91) were observed with NACT. In 22 observational studies, primary debulking surgery (PDS) yielded better OS (HR = 1.38, 95% CI: 1.19–1.60) but not progression-free survival (PFS) (HR = 1.03, 95% CI: 0.86–1.23). An increased optimal cytoreduction rate (HR = 1.17, 95% CI: 1.12–1.22) was observed with NACT. Irrespective of the degree of residual disease, OS was longer in the PDS group than that in the NACT group. Patients with FIGO stage III (HR = 1.43, 95% CI: 1.05–1.95) and IV (HR = 1.14, 95% CI: 1.06–1.23) disease had better survival with PDS. CONCLUSIONS: Treatment with NACT-IDS improves perioperative outcomes and optimal cytoreduction rates, but it may not improve OS. NACT-IDS is not inferior to PDS-CT in terms of survival outcomes in selected AOC patients. Future studies should focus on candidate selection for NACT.
format Online
Article
Text
id pubmed-5823572
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58235722018-02-28 The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies Qin, Meng Jin, Ying Ma, Li Zhang, Yan-Yan Pan, Ling-Ya Oncotarget Research Paper OBJECTIVE: We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients. MATERIALS AND METHODS: We searched PubMed, EMBASE, and the Cochrane Library for relevant articles. All statistical analyses were performed in Review Manager 5.3.5. RESULTS: In two randomized controlled trials (RCTs), there was no significant difference in overall survival (OS) (HR = 0.93, 95% CI: 0.81–1.06) or progression-free survival (PFS) (HR = 0.97, 95% CI: 0.86–1.09). Few adverse events (HR = 0.37, 95% CI: 0.19–0.72) and a high optimal debulking surgery rate (HR = 1.69, 95% CI: 1.50–1.91) were observed with NACT. In 22 observational studies, primary debulking surgery (PDS) yielded better OS (HR = 1.38, 95% CI: 1.19–1.60) but not progression-free survival (PFS) (HR = 1.03, 95% CI: 0.86–1.23). An increased optimal cytoreduction rate (HR = 1.17, 95% CI: 1.12–1.22) was observed with NACT. Irrespective of the degree of residual disease, OS was longer in the PDS group than that in the NACT group. Patients with FIGO stage III (HR = 1.43, 95% CI: 1.05–1.95) and IV (HR = 1.14, 95% CI: 1.06–1.23) disease had better survival with PDS. CONCLUSIONS: Treatment with NACT-IDS improves perioperative outcomes and optimal cytoreduction rates, but it may not improve OS. NACT-IDS is not inferior to PDS-CT in terms of survival outcomes in selected AOC patients. Future studies should focus on candidate selection for NACT. Impact Journals LLC 2017-12-27 /pmc/articles/PMC5823572/ /pubmed/29492221 http://dx.doi.org/10.18632/oncotarget.23808 Text en Copyright: © 2018 Qin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Qin, Meng
Jin, Ying
Ma, Li
Zhang, Yan-Yan
Pan, Ling-Ya
The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title_full The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title_fullStr The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title_full_unstemmed The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title_short The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
title_sort role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823572/
https://www.ncbi.nlm.nih.gov/pubmed/29492221
http://dx.doi.org/10.18632/oncotarget.23808
work_keys_str_mv AT qinmeng theroleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT jinying theroleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT mali theroleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT zhangyanyan theroleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT panlingya theroleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT qinmeng roleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT jinying roleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT mali roleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT zhangyanyan roleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies
AT panlingya roleofneoadjuvantchemotherapyfollowedbyintervaldebulkingsurgeryinadvancedovariancancerasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsandobservationalstudies